Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 4 for:    pbtz

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBTZ169 in Multiple Dosing

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03776500
Recruitment Status : Recruiting
First Posted : December 14, 2018
Last Update Posted : February 27, 2019
Sponsor:
Collaborator:
Bill and Melinda Gates Foundation
Information provided by (Responsible Party):
Innovative Medicines for Tuberculosis

Brief Summary:

This is a randomized, double-blind, placebo-controlled, multiple ascending dose study conducted at one study center in Switzerland.

Four (4) panels (A, B, C and D) of 8 male subjects (6 active and 2 placebo) each receiving multiple doses of PBTZ169 or a matching placebo, at increasing dose levels, once or twice daily.

Subjects will participate in only one panel. Blocks of 4 subjects (3 under active treatment, 1 under placebo) will be investigated in parallel. Panels will start sequentially.

Safety will be assessed throughout the study; serial ECGs and serial blood samples will be collected for the safety and PK assessment of PBTZ169.

Dose escalation will be allowed once the Trial Safety Board has determined that adequate safety and tolerability after each panel completion has been demonstrated to permit proceeding to the next panel.

In addition, a preliminary assessment of the drug interaction potential of PBTZ169 will be done by the measurement of inhibition or induction of human cytochromes through the metabolism of microdoses of standard probe substrates


Condition or disease Intervention/treatment Phase
Tuberculosis, Pulmonary Drug: PBTZ169 Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Safety, Tolerability and Pharmacokinetic Profile of PBTZ169 Formulated as Native Crystal Powder: Multiple Ascending Doses, Randomized, Placebo- Controlled, Parallel-group, Sequential Phase Ib Trial in Healthy Volunteers
Actual Study Start Date : February 21, 2019
Estimated Primary Completion Date : September 30, 2019
Estimated Study Completion Date : October 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tuberculosis

Arm Intervention/treatment
Experimental: Panel A - Active
N = 6, 150 mg twice daily of PBTZ169
Drug: PBTZ169
PBTZ169 crystalline supplied as powder for oral solution

Placebo Comparator: Panel A - Placebo
N = 2, 150 mg twice daily of PBTZ169 matching placebo
Drug: Placebo
matching placebo supplied as powder for oral solution

Experimental: Panel B - Active
N = 6, 300 mg twice daily of PBTZ169
Drug: PBTZ169
PBTZ169 crystalline supplied as powder for oral solution

Placebo Comparator: Panel B - Placebo
N = 2, 300 mg twice daily of PBTZ169 matching placebo
Drug: Placebo
matching placebo supplied as powder for oral solution

Experimental: Panel C - Active
N = 6, 600 mg once daily of PBTZ169
Drug: PBTZ169
PBTZ169 crystalline supplied as powder for oral solution

Placebo Comparator: Panel C - Placebo
N = 2, 600 mg once daily of PBTZ169 matching placebo
Drug: Placebo
matching placebo supplied as powder for oral solution

Experimental: Panel D - Active
N = 6, 600 mg twice daily of PBTZ169
Drug: PBTZ169
PBTZ169 crystalline supplied as powder for oral solution

Placebo Comparator: Panel D - Placebo
N = 2, 600 mg twice daily of PBTZ169 matching placebo
Drug: Placebo
matching placebo supplied as powder for oral solution




Primary Outcome Measures :
  1. Safety and tolerability of increasing multiple oral doses of PBTZ169 in healthy male adult subjects evaluated by Treatment Emergent Adverse Events (TEAEs). [ Time Frame: Days 0-17 ]
    Evaluation by thorough monitoring of Treatment Emergent Adverse Events (TEAEs) following doses of PBTZ169 crystalline or placebo


Secondary Outcome Measures :
  1. Relative oral bioavailability assessment of PBTZ169 in healthy male subjects after multiple dosing [ Time Frame: Days 0-17 ]
    Estimation from the ratio of area under plasma concentration curves (AUCs) determined after the administration of PBTZ169

  2. Pharmacokinetics (PK) of multiple oral doses of PBTZ169 using Cmax [ Time Frame: Days 0-17 ]
    Determination of non-compartmental PK parameter Maximum Plasma Concentration [Cmax] after determination of the amount of the parent compound and its known metabolites in plasma samples

  3. Pharmacokinetics (PK) of multiple oral doses of PBTZ169 using Tmax [ Time Frame: Days 0-17 ]
    Determination of non-compartmental PK parameter Time of maximum observed Plasma Concentration [Tmax] after determination of the amount of the parent compound and its known metabolites in plasma samples

  4. Metabolism interaction of multiple oral doses of PBTZ169 by measuring ratios of 7 probe substrates before the first and and after the last dose [ Time Frame: Days -1 to 14 ]
    Measurement of the ratios of 7 probe of known substrates of human Cytochome P-450 enzyme family before the first and and after the last dose



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 48 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male subjects aged between 18 and 48 years
  • Body weight (BW) ranging between 55 and 95 kg, providing body mass index (BMI) is between 18 and 28 kg/m2
  • Absence of significant findings in the medical history and physical examination as judged by the Investigator, especially for cardiovascular, pulmonary, haematological and nervous systems
  • Absence of significant laboratory abnormalities as judged by the Investigator. Gilbert's syndrome (increased total and unconjugated bilirubin when fasting) will be accepted if mild. Moderate creatine kinase increases (up to 600 IU/L) without clinical abnormalities, commonly found in physically active young males.
  • Absence of clinically significant abnormalities on 12-lead ECG
  • Negative urine drug screen (amphetamines, benzodiazepines, cannabis, cocaine, opiates)
  • Commitment to refrain from travel outside Europe over the whole study duration
  • Ability to understand the procedures, agreement to participate and willingness to give written informed consent
  • Co-operative attitude and availability for scheduled visits over the entire study period
  • Commitment to refrain from alcohol and tobacco consumption over the whole study period.

Exclusion Criteria:

  • History of major cardiovascular, pulmonary, hepatic, immunological, renal, haematological, gastrointestinal, genitourinary, neurological, or rheumatologic disorders
  • Active diseases of any type, including inflammatory disorders and infections. Mild acne is permissible providing no systemic or local treatment is provided or planned (except for cleaning lotions)
  • History of significant allergy or asthma. Allergic rhinitis or conjunctivitis is acceptable if non-symptomatic when starting the study and if symptoms are not anticipated to occur during the study to a point that would require corticosteroid therapy (e.g. in case of annual use)
  • History of cardiovascular dysfunction if considered as clinically relevant (conduction abnormality, arrhythmia, bradycardia, angina pectoris, cardiac hypertrophy unless elicited by training, pulmonary embolism)
  • Hypertension defined as supine blood pressure >150/90 mmHg or recurrent hypotensive events considered as clinically relevant or documented orthostatic hypotension
  • Sick sinus syndrome, known long QT syndrome, reproducible observation of corrected QT interval QTc ≥440 msec or of pronounced sinus bradycardia (<40 bpm/min)
  • Intense sport activities. Moderate sport is acceptable and activities should remain fairly constant throughout the study
  • Any clinically significant laboratory values on screening that are not within normal range on single repeat (Gilbert's syndrome or CK elevations usually acceptable if moderate)
  • Positive hepatitis B and C antigen screen
  • Positive HIV antibody screen or screen not performed
  • Any recent acute illness or sequelae thereof which could expose the subject to a higher risk or might confound the results of the study, according to the evaluation of the investigator
  • Treatment in the previous three months with any drug known to have well-defined potential for toxicity to a major organ
  • History of hypersensitivity to any drug if considered as serious
  • Use of any medication the week prior to study or as based on the 5 plasma half-life rule and throughout study, including aspirin or other over-the-counter (OTC) preparations. Paracetamol is permissible before and during the study as a rescue medication but only with Investigator's permission
  • Participation in a clinical investigation or blood donation of 500 ml within the past 3 months
  • History of relevant alcohol or drug abuse
  • Usual smoking during the last month before participation in the study. Consumption of ≤5 cigarettes/day or equivalent is acceptable providing the subject can totally refrain from smoking from one week before and during the whole study duration
  • Usual consumption of a large quantity of coffee, tea, chocolate (more than 4 cups/day) or equivalent (Cola drinks), during the last month before participation in the study
  • Current regular (i.e. 3 times per week or more) consumption of large quantities of alcohol or wine (>0.5 L wine/day) or equivalent (i.e. more than 50 g ethanol per day), during the last month before participation in the study. Alcohol is not allowed during the whole study period
  • Project to conceive a child during the study period (by principle of precaution, while no indication exists for a definite reproductive risk following paternal exposure)
  • Psychological status which could impact on the subject's ability to give informed consent
  • Any feature of the subject's medical history or present condition which, in the Investigator's opinion, could confound the results of the study, complicate its interpretation, or represent a potential risk for the subject.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03776500


Locations
Layout table for location information
Switzerland
Division of Clinical Pharmacology, Centre Hospitalier Universitaire Vaudois (CHUV) Recruiting
Lausanne, Vaud, Switzerland, 1011
Contact: Thierry Buclin, Prof    021 314 4261 ext 0041    Thierry.Buclin@chuv.ch   
Sponsors and Collaborators
Innovative Medicines for Tuberculosis
Bill and Melinda Gates Foundation

Layout table for additonal information
Responsible Party: Innovative Medicines for Tuberculosis
ClinicalTrials.gov Identifier: NCT03776500     History of Changes
Other Study ID Numbers: IM-006-13
First Posted: December 14, 2018    Key Record Dates
Last Update Posted: February 27, 2019
Last Verified: December 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Tuberculosis
Tuberculosis, Pulmonary
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections